Document Detail

Antithrombin III concentrates--are they clinically useful?
MedLine Citation:
PMID:  7667814     Owner:  NLM     Status:  MEDLINE    
Treatment with AT III concentrates is a good example for the discrepancy between the optimistic expectations based on theoretical considerations or animal experiments and the result of clinical studies. 15 years after the introduction into clinical practice, a benefit for patients treated with AT III concentrates has not been proven. In hereditary antithrombin III deficiency, randomized clinical trials are completely lacking and only few and small sized randomized studies were performed in patients with acquired AT III deficiency. In none of these trials, a significant clinical benefit with regard to reduction of morbidity or mortality was detectable. Based on the published data, one can state that AT III concentrates may be beneficial in some special clinical situations in patients with hereditary antithrombin III deficiency (such as delivery, acute serious thromboembolic complications and postoperative thromboprophylaxis). In acquired AT III deficiency, there is no proven indication for the use of AT III concentrates.
K Lechner; P A Kyrle
Related Documents :
20099594 - Efficacy of aerial spray applications using fuselage booms on air force c-130h aircraft...
16855994 - Humidified air inhalation for treating croup.
7284544 - Clinical trials:randomization before consent.
19582904 - Under the gun.
25178534 - Recovery in knee range of motion reaches a plateau by 12 months after total knee arthr...
9669264 - Emergent balloon mitral valvotomy in patients presenting with cardiac arrest, cardiogen...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  73     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  1995 Mar 
Date Detail:
Created Date:  1995-10-11     Completed Date:  1995-10-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  340-8     Citation Subset:  IM    
Department of Medicine I, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antithrombin III / isolation & purification,  pharmacokinetics,  therapeutic use*
Antithrombin III Deficiency
Asparaginase / adverse effects
Clinical Trials as Topic
Genetic Predisposition to Disease
Infant, Newborn
Kidney Diseases / metabolism,  therapy
Liver Diseases / metabolism,  therapy
Postoperative Complications / prevention & control
Pregnancy Complications, Hematologic / therapy
Randomized Controlled Trials as Topic
Shock, Septic / therapy
Thromboembolism / genetics,  prevention & control*
Reg. No./Substance:
9000-94-6/Antithrombin III; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Growth hormone in adults. An elixir of youth?
Next Document:  Fibrin polymerization defect in HIV-infected patients--evidence for a critical role of albumin in th...